Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of hepato-biliary-pancreatic sciences"
DOI: 10.1002/jhbp.1135
Abstract: Optimal strategies for advanced HCC tumors, such as those with vascular tumor thrombus and those with extrahepatic metastases, are unclear. Upfront surgical resection of such tumors has been challenged at some institutions because of lack… read more here.
Keywords: conversion surgery; therapy; unresectable hcc; conversion ... See more keywords
Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study
Sign Up to like & getrecommendations! Published in 2023 at "World Journal of Gastrointestinal Oncology"
DOI: 10.4251/wjgo.v15.i4.689
Abstract: BACKGROUND Although immune checkpoint inhibitor (ICI) therapy has improved the prognosis of unresectable hepatocellular carcinoma (HCC), it has also resulted in unique immune-related adverse events (irAEs). The relationship between irAE and treatment outcomes in ICI-treated… read more here.
Keywords: patients unresectable; immune related; related adverse; unresectable hcc ... See more keywords